Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triac Trial II in young children with MCT8 deficiency
2024-516123-13-00Phase 2Authorised
- Sponsor
- Egetis Therapeutics
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of tiratricol in Allan-Herndon-Dudley syndrome (AHDS), sponsored by Egetis Therapeutics. Primary endpoints: GMFM-88 total score and BSID-III Gross Motor Skill Domain. Planned start Feb 2021; status: authorised.
02
Drugs
tiratricol
03
Conditions
Allan-Herndon-Dudley syndrome (AHDS)
Beyond the preview
Go deeper on 2024-516123-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516123-13-00.